For sponsors with a study behind schedule
Nobody can tell you why your enrollment is slow, because nobody is measuring the funnel.
An under-enrolling study has one of four problems: not enough qualified traffic, pre-screening that leaks, sites that can't schedule what they're sent, or eligibility criteria that were never realistic. Most sponsors spend more money before they know which one it is.
Where to go next
Rescue
Your study is behind. Start here.
Diagnostic guides for under-enrolling studies: where the funnel is actually breaking, when to replace a vendor, and when adding sites makes things worse.
Analysis
What the public record shows
Termination and withdrawal reasons, enrollment timelines by phase and therapeutic area, site count versus real pace — built entirely from ClinicalTrials.gov and FDA data.
Companies
Who does patient recruitment, and how
Profiles of the companies sponsors hire when a study is behind: operating model, where each is strong, where each is a poor fit, and what to ask before signing. CT Scan, this site's owner, is listed among them and assessed on the same criteria.
Glossary
The terms, defined honestly
Cost per lead versus cost per randomization. Screen-fail rate. Recruitment versus enrollment. The vocabulary vendors use loosely and sponsors get billed against.
Why this publication exists
Enrollment failure is the most expensive routine event in drug development, and it is covered almost entirely by the companies selling the fix. Vendor content explains what a vendor sells. It rarely explains how to tell whether the vendor is the problem.
Rock Enroll is published by CT Scan, Inc., which operates DYNO. We say so on every page, and CT Scan is covered here on the same criteria as the companies it competes with. Where we take a position, we publish the evidence for it first.